Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Plos One|July 27, 2010
Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapyLaurence Weiss, Christophe Piketty, Lambert Assoumou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 16, 2019
Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported Plasmodium falciparum Malaria in FranceNermine El Ket, Eric Kendjo, Marc Thellier, et al.
AIDS (London, England)|July 18, 2015
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremiaAmélie Guihot, Chiara Dentone, Lambert Assoumou, et al.
AIDS (London, England)|February 27, 2015
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremiaLaure Campillo-Gimenez, Lambert Assoumou, Marc-Antoine Valantin, et al.
The Journal of Antimicrobial Chemotherapy|April 24, 2024
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial)Emuri Abe, Roland Landman, Lambert Assoumou, et al.
Journal of Infection and Public Health|September 8, 2025
Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study - IMEA 057Minh P Lê, Clotilde Allavena, Véronique Joly, et al.
The Journal of Infectious Diseases|June 24, 2021
HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 InfectionJade Ghosn, Lambert Assoumou, Caroline Lascoux-Combe, et al.
AIDS (London, England)|November 16, 2010
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccineLaura Papagno, Galit Alter, Lambert Assoumou, et al.
AIDS (London, England)|October 20, 2009
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trialElisabeth Aslangul, Lambert Assoumou, Randa Bittar, et al.
AIDS (London, England)|June 27, 2008
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran, Robert L Murphy, Dominique Costagliola, et al.
Pageof 13